We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Gap in the Shire

19 August 2005 By Robert Cyran

The UK pharma group wants rival Barr to delay introducing a generic copy of the hyperactivity drug that provides nearly half its revenues. Buying off its rival will not come cheap. But this is a necessary step to keep the cash flowing until sales of new drugs kick in.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)